Keytruda biosimilars are coming — but they face an uphill battle
A patent cliff is fast approaching for Merck’s flagship blockbuster, but the deck might be stacked against its biosimilars gaining widespread traction.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.